Read the latest edition online
The 50 hottest disruptive technology companies
In a move to provide desperately needed life science space in Cambridge, Chesterford Research Park has submitted plans for a new three-storey hub on a plot to the east of the park.
Subject to planning, the c60,000 sq ft multi-occupier building will be fitted with a mix of laboratory and office space and be ready for occupation in the summer of 2024.
Named the Sidney Sussex Building, the proposal for Plot 800 aims to satisfy existing and future requirements for additional fitted laboratory and write-up space within the park.
The building will deliver individual, flexible suites from 2,226 sq ft to 8,409 sq ft which will enable both the expansion of existing park occupiers as well as attracting new ventures. The building has also been designed to allow for spaces to be combined to facilitate larger requirements.
In addition to open plan write up/admin areas, benching, lifts, storage rooms and shower facilities, all suites will have access to a central, communal light-filled atrium which includes a dedicated reception area.
Sustainability and environmental considerations are integral to the proposal both inside and out. Renewable energy, efficient use of structure, thoughtful materiality, and daylighting strategies inform the building design to minimise carbon emissions.
Ecological enhancements such as significant tree planting, bird and bat boxes and a new pond will provide homes for wildlife and green space for occupiers whilst delivering an overall biodiversity net gain.
Julian Cobourne, head of Regional Offices, Aviva Investors – joint owners of Chesterford Research Park with Uttlesford District Council – said: “Our plans for the Sidney Sussex Building reflect the strong demand we continue to see for high-quality, well-connected physical facilities in one of the most dynamic markets in the UK.
“We believe that extending the facilities at Chesterford Research Park will have a positive impact on the local economy, whilst also cementing the park’s position as a destination of choice for some of the leading life science businesses globally. We look forward to working with local groups and project partners to bring this exciting development to fruition.”
Chesterford Research Park provides a much-heralded environment for innovative research and development for both established and early-stage biotechnology and pharmaceutical companies.
It is home to life science and technology innovators including Arecor, AstraZeneca, Cambridge Epigenetix, Charles River Laboratories, Domainex, Illumina and Lonza.
Aviva Investors and Uttlesford District Council are advised by Chesterford Research Park’s joint commercial agents, Savills and Cheffins and developer The Churchmanor Estates Company plc.
• CGI courtesy of Chesterford Research Park
Stay informed of the latest news and features